PMDA — authorised 29 June 2020
- Marketing authorisation holder: Sanofi K.K.
- Status: approved
🇯🇵 Hu38Sb19 in Japan
PMDA authorised Hu38Sb19 on 29 June 2020
Marketing authorisation
Hu38Sb19 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in Japan
Frequently asked questions
Is Hu38Sb19 approved in Japan?
Yes. PMDA authorised it on 29 June 2020.
Who is the marketing authorisation holder for Hu38Sb19 in Japan?
Sanofi K.K. holds the Japanese marketing authorisation.